Regulus Therapeutics Inc.: insider trades · United States · SEC (Form 4)

About Regulus Therapeutics Inc.

Regulus Therapeutics Inc. is a U.S.-listed biotechnology company traded on NASDAQ in the United States, with its principal executive offices in San Diego, California. The company was originally formed in September 2007 as Regulus Therapeutics LLC and later converted into a corporation. Since inception, Regulus has been built around a highly specialized scientific thesis: microRNA-targeting therapeutics. Its core strategy is to develop oligonucleotide medicines designed to inhibit dysregulated microRNA pathways, with the goal of addressing genetically defined orphan diseases. Regulus has progressively concentrated its research and development efforts on inherited kidney disorders, especially autosomal dominant polycystic kidney disease (ADPKD), a rare disease with significant unmet medical need. The company’s technology base stems from exclusive intellectual property licensed from Alnylam and Ionis, two prominent names in the oligonucleotide field, while also incorporating internal discoveries made over time. This gives Regulus a differentiated platform centered on microRNA biology, kidney targeting, and anti-miR chemistry. Its lead clinical asset is farabursen (RGLS8429), which is being evaluated in a Phase 1b clinical trial in ADPKD. Regulus positions farabursen as a next-generation anti-miR-17 therapy intended to address the underlying biology of the disease by inhibiting miR-17, thereby supporting higher expression of PC1 and PC2 proteins and potentially reducing cyst growth. This is a focused but scientifically ambitious approach, and it places the company in a competitive but niche segment of the biotech market where a successful clinical readout could be highly value-accretive. From a business perspective, Regulus remains a clinical-stage, single-asset-focused biotech company, which means it carries the typical risks of small-cap drug developers: financing needs, regulatory uncertainty, trial execution risk, and dependence on a narrow pipeline. At the same time, its concentrated focus on an orphan kidney disease, its microRNA expertise, and the possibility of differentiation versus standard care provide a clear strategic identity. The company has also highlighted the potential commercial relevance of combining its approach with tolvaptan, the only FDA-approved drug for ADPKD. Recent corporate developments are particularly important. In April 2025, Regulus announced an agreement to be acquired by Novartis AG, and in May 2025 it reported first-quarter 2025 financial results and recent updates. For investors, this means the story is no longer solely about early clinical development: the company is now also shaped by the pending strategic transaction, alongside ongoing clinical and regulatory milestones. Overall, Regulus Therapeutics is best viewed as a U.S. NASDAQ-listed biotech with a distinctive microRNA platform, a focused kidney-disease pipeline, and a current investment case dominated by both clinical progress and acquisition dynamics.